Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Change in Acquisitions & Divestments came in at $209.0 million in Q1 2026, down 4.13% year-on-year from $218.0 million in Q1 2025, and down 4.57% quarter-over-quarter from $219.0 million in Q4 2025.

Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $209.0 million for Q1 2026.

  • Change in Acquisitions & Divestments for Q1 2026 came in at $209.0 million, down 4.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 2.88% YoY), and the FY2025 annual result was $1.7 billion, down 32.53% from the prior year.
  • Change in Acquisitions & Divestments came in at $209.0 million for Q1 2026 at Johnson & Johnson, down from $219.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $24.8 billion in Q1 2023 to a low of $209.0 million in Q1 2026.
  • The 5-year median for Change in Acquisitions & Divestments is $735.0 million (2025), against an average of $3.7 billion.
  • Across the five-year window, Change in Acquisitions & Divestments climbed 23.21% in 2023 and tumbled 91.95% in 2024, its largest moves.
  • Johnson & Johnson's Change in Acquisitions & Divestments stood at $6.3 billion in 2022, then sank by 42.84% to $3.6 billion in 2023, then sank by 91.95% to $290.0 million in 2024, then dropped by 24.48% to $219.0 million in 2025, then declined by 4.57% to $209.0 million in 2026.
  • The last three Change in Acquisitions & Divestments figures came in at $209.0 million (Q1 2026), $219.0 million (Q4 2025), and $489.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 209.00 Mn
Mar 29, 2026 209.00 Mn
Dec 28, 2025 219.00 Mn
Dec 28, 2025 219.00 Mn
Sep 28, 2025 489.00 Mn
Sep 28, 2025 489.00 Mn
Jun 29, 2025 735.00 Mn
Jun 29, 2025 735.00 Mn
Mar 30, 2025 218.00 Mn
Mar 30, 2025 218.00 Mn
Dec 29, 2024 290.00 Mn
Dec 29, 2024 290.00 Mn
Sep 29, 2024 466.00 Mn
Sep 29, 2024 466.00 Mn
Jun 30, 2024 727.00 Mn
Jun 30, 2024 727.00 Mn
Mar 31, 2024 979.00 Mn
Mar 31, 2024 979.00 Mn
Dec 31, 2023 3.60 Bn
Dec 31, 2023 3.60 Bn